Oncology

Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.

Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.

Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.

Review top news and interview highlights from the week ending September 16, 2022.

A single-center study assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.

The announcement comes after positive top-line results in the ongoing KarMMa-3 study.

MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.

The FDA authorized the natural killer cell therapy combo for compassionate use.

Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.

The 5-year relapse-free survival rate was 22.3% with T-VEC prior to surgery, compared with 15.2% for surgery alone.

Of the 8 treated patients who were evaluable, 6 patients had stable disease at Day 28.

Based on the findings, investigators are considering registration with the FDA and EMA.

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.

Among the 31 patients evaluable for efficacy analysis, ORR was 100%.

A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.

Review top news and interview highlights from the week ending September 9, 2022.

BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.

The director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.

SLN124 was well-tolerated in a previous clinical trial involving healthy volunteers.

Patients receiving CAR T-cell therapy or bispecific antibody therapies as first salvage therapy had an ORR of 84%.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has requested additional preclinical data from Beam Therapeutics on BEAM-201.

Of 55 evaluable patients in ZUMA-3, 71% achieved complete remission (CR) or CR with incomplete hematological recovery (CRi).